Opioid use disorder (OUD) has reached epidemic proportions in the United States, with related deaths, health care costs, and economic burden escalating at a rapid pace (see The Magnitude of the Growing U.S. Opioid Epidemic1-3). In addition to the adverse physical and emotional effects experienced by those who have the disorder, the negative societal effects of OUD are substantial as well. People with OUD often find themselves unable to maintain steady employment or take care of themselves or their families.
The Centers for Disease Control and Prevention (CDC) describes the rise in opioid use and overdose deaths as having occurred in three phases4:
- In the 1990s, an increase in prescriptions of opioids for chronic pain coincided with a rise in overdose deaths from prescribed opioids.
- 2010 saw a rapid increase in overdose deaths from heroin.
- 2013 marked the start of a significant rise in overdose deaths involving synthetic opioids, particularly illicit fentanyl.
The rate of opioid overdose deaths in the United States continues to rise, challenging health care providers. In response to this alarming escalation, in 2016 the CDC introduced the CDC Guideline for Prescribing Opioids for Chronic Pain, which sought to clarify evidence-based recommendations for using opioids to manage pain in adults ages 18 and older who are receiving treatment outside of a palliative or end-of-life care setting.5 By mid-2017, 23 states had limited opioid prescribing in some way, with most setting a maximum number of days (ranging from three to 14) for first-time opioid prescriptions and many requiring prescribers to review their state's prescription drug monitoring program (PDMP) before prescribing to determine whether patients were receiving opioids from other prescribers, thereby increasing their risk of overdose or of developing OUD.6 In April 2018, the National Institutes of Health launched the Helping to End Addiction Long-Term (HEAL) Initiative, which supports research into strategies that prevent and treat OUD and improve pain management.7 This article discusses OUD pathophysiology and medical treatments, as well as the screening tools and behavioral interventions that can help nurses support patients in overcoming OUD.
PATHOPHYSIOLOGY OF OUD
OUD is a chronic relapsing disease influenced by such factors as genetics, stress system response, and prior opioid experimentation or increasing exposure.8 In the United States, nearly 80% of current heroin users report they previously used an opioid medication for nonmedical reasons.9, 10 Prolonged or increasing exposure to opioids is associated with tolerance, dependence, and addiction (see Drug Use Terminology11).
Development of OUD. Current research emphasizes the roles pleasure seeking and pain avoidance play in the development of OUD. Piazza and Deroche-Gamonet point out that humans invest a great deal of time and money in recreational activities, such as sports, music-related activities, visual entertainment, and gourmet food, which are designed specifically to produce feelings of pleasure by altering brain activity, typically through the five senses.12 They suggest that using drugs, such as opioids, can be seen as another form of recreation in which brain activity is similarly altered, though the alteration occurs as a direct result of the pharmacological substance rather than through the sensory system.
From usage to addiction. Piazza and Deroche-Gamonet posit that the transition to addiction occurs in three stages12:
- recreational drug use, in which drug intake is moderate and sporadic and only one among many recreational activities the person engages in
- intensified drug use, in which drug intake escalates and becomes a primary recreational activity; while social and personal functioning are diminished, behavior remains generally under control
- addiction, in which control over drug use is lost and behavior is largely focused on drug seeking and drug taking
The first phase occurs in most people who use psychoactive drugs for nonmedical purposes, as these drugs stimulate a release of rewarding neurotransmitters. The second phase occurs in a portion of those people whose brains have a hyperactive dopaminergic (reward) system and an impaired prefrontal cortex (suggestive of increased impulsivity). The third and final phase is associated with impaired neuronal structure and signaling in the brain's reward-related areas that create such an intense need for the drug that its absence causes intense suffering.
NEUROBIOLOGY OF OPIOID USE
Under normal circumstances, the prefrontal cortex of the brain, which mediates cognitive, emotional, and behavioral functioning, stops us from pursuing pleasure from behaviors that may be overly risky. Prefrontal cortex feedback, however, may be compromised in people with OUD.13, 14
The action of opioids on neuronal receptors. Opioids stimulate the brain's mesolimbic dopaminergic system, as well as other systems, by attaching to neuronal opioid receptors. There are three opioid receptor subtypes: mu, kappa, and delta, in addition to the nociceptin opioid receptor, formerly known as opioid receptor like-1.15, 16
Opioids attach to mu receptors in the brain's ventral tegmental area, increasing the release of the neurotransmitter dopamine into the brain's nucleus accumbens, which is involved with reward, dopamine release, and stimulant action (see Figure 1).14 The release of dopamine into the nucleus accumbens creates pleasurable feelings, thereby rewarding the drug-taking behavior, which may explain why opioids are often taken frequently in the initial stages of opioid use.14 Opioids also elevate dynorphin neuropeptide levels, which activate the kappa receptors, reducing dopamine transmission and creating feelings of dysphoria (unease or dissatisfaction). This may explain why opioid users often take additional opioids in an attempt to reverse the unpleasant psychological feelings brought on by kappa receptor activation.17
Endogenous versus exogenous opioids. Normally, in response to behaviors that promote healthy living, such as exercise, eating, and sexual activity, the brain produces endorphins, which stimulate the release of endogenous opioids, such as dopamine, in order to reward those healthy behaviors. Exogenous opioids, such as heroin, stimulate the brain to release more dopamine than is released as a natural reward, causing the brain to make adaptations to neuronal structure and signaling. It's been suggested that, eventually, these adaptations raise the “set point” at which dopamine is released so that normally pleasurable activities are no longer enjoyable in the absence of exogenous opioids.14 The negative physical and psychological effects of drug withdrawal are felt to be so intolerable that drug use often continues despite immense negative consequences, and chronic relapse may occur even long after acute withdrawal.13
The hypothalamic–pituitary–adrenal (HPA) axis. Opioids can substantially disrupt the HPA axis, which controls the body's response to stress (see Figure 218-20). The combined effects of HPA axis disruption; the development of tolerance, dependence, and addiction; and the adaptations that the brain makes to cope with a massive influx of exogenous opioids make it extremely challenging for people with OUD to remain drug free. Recognizing these challenges can help nurses better understand the behavior of patients with OUD and empathize with their struggle to overcome this disorder.
Patients with signs or symptoms of acute opioid use or withdrawal and those presenting with conditions or adverse events associated with chronic opioid use should raise nurses' index of suspicion for OUD (see Recognizing Opioid Use and Withdrawal21).
SCREENING FOR OPIOID USE
Several screening tools are available to help nurses assess patients for OUD. These include
The following behavioral and counseling techniques have demonstrated efficacy in reducing substance use and, when combined with pharmacotherapy, often provide enormous positive outcomes:
- Motivational interviewing–a counseling technique that helps patients with OUD work through ambivalence about their drug use and develop motivation to change their behavior.22
- Cognitive behavioral therapy–a technique that helps patients with OUD identify triggers for relapse by helping them focus on their current situation and learn relaxation exercises and social techniques that support their recovery efforts.23
- Contingency management–the use of tangible rewards, such as cash prizes or vouchers to foster positive behaviors.24
Motivational interviewing is a patient-centered, directive method of counseling that helps patients strengthen their motivations to change by exploring and resolving their ambivalence to change.25 This technique provides practitioners with a guideline for assessing patients' readiness to change as well as suggestions for encouraging positive health choices. Motivational interviewing is used to identify the stage of change a patient with OUD is experiencing. Its basic principles are as follows22:
- Resist the “righting reflex,” that is, avoid the tendency to tell patients with OUD that they should stop using opioids and instead initiate a conversation that will allow them to verbalize reasons they should stop using.
- Understand patients' motivations and show interest in their concerns, as this will motivate them to stop using.
- Listen to patients and empathize; their ability to stop using opioids starts with their decision to do so.
- Empower patients by helping them identify a plan to stop using.
Motivational interviewing can enable nurses to use patients' objective behavior to determine their stage in the disease process, their readiness to change, the internal processes they may be experiencing, appropriate goals, and questions that can prompt them to take positive actions (see Table 122, 26). Although motivational interviewing can be learned from a book, proper training and practice produce better results.25
People with OUD need access to a variety of treatment modalities to remain free from opioid use. Medication, mental health services, medical care, addiction counseling, and recovery support services work together to provide a holistic approach.21 Unfortunately, medication-assisted treatment is greatly underused and there are still providers who encourage an abstinence-only approach. For instance, according to the Substance Abuse and Mental Health Services Administration's Treatment Episode Data Set 2002-2012, the proportion of heroin admissions with treatment plans that included receiving medication-assisted opioid therapy fell from 35.2% in 2002 to 27.6% in 2012.27 The slow adoption of these evidence-based treatment options for opioid dependence is partly due to misconceptions about substituting one drug for another.21 The goal of medication maintenance therapy for opioid addiction is to help patients with OUD avoid withdrawal symptoms and minimize cravings, allowing them to achieve their rehabilitation goals, reconnect with family and friends, and return to a productive lifestyle. Medications prescribed for opioid addiction fall into three classes: full mu-opioid agonists, partial mu-opioid agonists, and mu-opioid antagonists (see Table 221, 28).
The full mu-opioid agonist methadone occupies the opioid receptor in the same way morphine does but has a much longer duration of action, with a half-life of eight to 59 hours (approximately 55 hours in opioid-naive patients and 24 hours in opioid-tolerant patients) versus morphine's half-life of one to five hours.29 Methadone's longer duration of action normalizes the HPA axis, minimizes opioid withdrawal symptoms and cravings, inhibits the effect of illicit opioids, and reduces the risks associated with compulsive opioid use. The partial mu-opioid agonist buprenorphine, often prescribed in a combination formulation with the opioid antagonist naloxone, provides similar advantages to those of methadone, but as a partial agonist, it's less likely than a full agonist to cause respiratory depression. The mu-opioid antagonist naltrexone attaches to the opioid receptor but causes no opioid effects, essentially blocking the effect of opioids and, thereby, preventing patients with OUD from experiencing the “high” of opioid administration.21
Several studies have shown that substance use disorders are more stigmatized than other chronic diseases and that health care providers often have negative attitudes toward patients with such disorders.30-32 Providing health care providers with information on the pathophysiology of opioid addiction, treatment options and programs, and the importance of empathic listening is key to breaking the cycle of shame and blame associated with OUD (see Online Resources for Nurses). Nurses can play a pivotal role in advocating the use of OUD screening tools, motivational interviewing, and appropriate treatment for patients with this chronic, relapsing disorder.
Online Resources for Nurses
Substance Abuse and Mental Health Services Administration
Directory of inpatient treatment providers: http://findtreatment.samhsa.gov
U.S. Department of Veterans Affairs
Locations of programs for veterans with substance use disorders: www.va.gov/directory/guide/SUD.asp
Information and Research Initiatives
National Institutes of Health
The Helping to End Addiction Long-Term (HEAL) Initiative: https://heal.nih.gov
National Institutes of Health/National Institute on Drug Abuse
Understanding Drug Use and Addiction: www.drugabuse.gov/publications/drugfacts/understanding-drug-use-addiction
1. Florence CS, et al. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care
2. Rudd RA, et al. Increases in drug and opioid-involved overdose deaths—United States, 2010-2015. MMWR Morb Mortal Wkly Rep
3. National Institute on Drug Abuse. What is the scope of heroin use in the United States?
Rockville, MD: National Institutes of Health; 2018 Jun. https://www.drugabuse.gov/publications/research-reports/heroin/scope-heroin-use-in-united-states
4. Centers for Disease Control and Prevention. 2018 annual surveillance report of drug-related risks and outcomes—United States. Surveillance special report
. Atlanta; 2018 Aug 31. https://www.cdc.gov/drugoverdose/pdf/pubs/2018-cdc-drug-surveillance-report.pdf
5. Dowell D, et al. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep
6. Bendix J. Opioid policy fallout. Med Econ
7. National Institutes of Health. NIH launches HEAL Initiative, doubles funding to accelerate scientific solutions to stem national opioid epidemic [press release]. 2018 Apr 4. https://www.nih.gov/news-events/news-releases/nih-launches-heal-initiative-doubles-funding-accelerate-scientific-solutions-stem-national-opioid-epidemic
8. Reed B, et al. Neurobiology of opiates and opioids. In: The American Psychiatric Publishing textbook of substance abuse treatment
. 4th ed. Washington, DC: American Psychiatric Publishing; 2008. p. 277–94.
9. Jones CM.Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers—United States, 2002-2004 and 2008-2010. Drug Alcohol Depend 2013;132(1–2):95–100.
10. Muhuri PK, et al. Associations of nonmedical pain reliever use and initiation of heroin use in the United States
. Rockville, MD; 2013 Aug. CBHSQ data review; https://www.samhsa.gov/data/sites/default/files/DR006/DR006/nonmedical-pain-reliever-use-2013.htm
11. National Institute on Drug Abuse. The science of drug use and addiction: the basics [media guide]
. Rockville, MD: National Institutes of Health; 2018 Jul. https://www.drugabuse.gov/publications/media-guide/science-drug-use-addiction-basics
12. Piazza PV, Deroche-Gamonet V. A multistep general theory of transition to addiction. Psychopharmacology (Berl)
13. Koob GF. Negative reinforcement in drug addiction: the darkness within. Curr Opin Neurobiol
14. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect
15. Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology
16. Koob GF. A role for brain stress systems in addiction. Neuron
17. Wilson-Poe AR, Morón JA. The dynamic interaction between pain and opioid misuse. Br J Pharmacol
18. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med
19. Milivojevic V, Sinha R. Central and peripheral biomarkers of stress response for addiction risk and relapse vulnerability. Trends Mol Med
20. Kreek MJ, Koob GF. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend
21. Substance Abuse and Mental Health Services Administration. TIP 63: Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families
. Rockville, MD; 2018. HHS Publication No. (SMA) 18-5063FULLDOC.
22. Rollnick S, et al. Motivational interviewing principles and evidence. In: Motivational interviewing in health care: helping patients change behavior
. New York, NY: Guilford Press; 2008. p. 3–10.
23. McHugh RK, et al. Cognitive behavioral therapy for substance use disorders. Psychiatr Clin North Am
24. Petry NM, Martin B. Low-cost contingency management for treating cocaine- and opioid-abusing methadone patients. J Consult Clin Psychol
25. Burke BL, et al. The efficacy of motivational interviewing: a meta-analysis of controlled clinical trials. J Consult Clin Psychol
26. Jones-Smith E. Motivational interviewing and the stages of change theory. In: Theories of counseling and psychotherapy: an integrative approach
. 2nd ed. Los Angeles: SAGE 2016. p. 319–44.
27. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2002-2012. National admissions to substance abuse treatment services
. Rockville, MD; 2014 Jul. BHSIS Series S-71, HHS Publication No. (SMA) 14-4850.
28. Roxane Laboratories. Prescribing information: DOLOPHINE (methadone hydrochloride) tablets, for oral use CII
; 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/006134s038lbl.pdf
29. Grissinger M. Keeping patients safe from methadone overdoses. P T
30. Avery JD, et al. Attitudes toward individuals with mental illness and substance use disorders among resident physicians. Prim Care Companion CNS Disord
31. Mendiola CK, et al. An exploration of emergency physicians' attitudes toward patients with substance use disorder. J Addict Med
32. Morgan BD. Nursing attitudes toward patients with substance use disorders in pain. Pain Manag Nurs